Dockside LLC Invests $1.85 Million in Ralliant Corporation $RAL

Dockside LLC bought a new stake in shares of Ralliant Corporation (NYSE:RAL) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 36,246 shares of the company’s stock, valued at approximately $1,845,000.

Several other hedge funds have also modified their holdings of RAL. Viking Global Investors LP purchased a new stake in shares of Ralliant during the 2nd quarter valued at about $257,200,000. State Street Corp purchased a new stake in shares of Ralliant during the 2nd quarter valued at about $213,096,000. Norges Bank purchased a new stake in shares of Ralliant during the 4th quarter valued at about $124,687,000. Invesco Ltd. raised its holdings in shares of Ralliant by 90.1% during the 3rd quarter. Invesco Ltd. now owns 3,871,690 shares of the company’s stock valued at $169,309,000 after buying an additional 1,835,128 shares during the period. Finally, UBS Group AG raised its holdings in shares of Ralliant by 660.3% during the 3rd quarter. UBS Group AG now owns 1,865,072 shares of the company’s stock valued at $81,560,000 after buying an additional 1,619,770 shares during the period.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on RAL shares. Zacks Research upgraded Ralliant from a “strong sell” rating to a “hold” rating in a report on Monday, April 13th. Morgan Stanley raised their target price on Ralliant from $45.00 to $68.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. Wall Street Zen lowered Ralliant from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Royal Bank Of Canada raised their price objective on Ralliant from $47.00 to $64.00 and gave the company a “sector perform” rating in a research note on Wednesday, May 13th. Finally, Truist Financial restated a “buy” rating and set a $68.00 price objective (up from $53.00) on shares of Ralliant in a research note on Wednesday, May 13th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $67.30.

Ralliant Price Performance

Shares of NYSE RAL opened at $66.00 on Friday. Ralliant Corporation has a fifty-two week low of $37.27 and a fifty-two week high of $67.01. The business has a 50 day moving average price of $53.04 and a two-hundred day moving average price of $49.83. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. The firm has a market cap of $7.39 billion and a PE ratio of -6.03.

Ralliant (NYSE:RAL) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. The firm had revenue of $534.60 million during the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The business’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Sell-side analysts expect that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th will be given a $0.05 dividend. The ex-dividend date is Monday, June 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is presently -1.83%.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.